Ferrocifen stealth LNCs and conventional chemotherapy: A promising combination against multidrug-resistant ovarian adenocarcinoma - Institut Curie Accéder directement au contenu
Article Dans Une Revue International Journal of Pharmaceutics Année : 2022

Ferrocifen stealth LNCs and conventional chemotherapy: A promising combination against multidrug-resistant ovarian adenocarcinoma

Résumé

Ovarian cancer is one of the deadliest epithelial malignancies in women, owing to the multidrug resistance that restricts the success of conventional chemotherapy, carboplatin and paclitaxel. High grade serous ovarian carcinoma can be classified into two subtypes, the chemosensitive High OXPHOS and the Low OXPHOS tumour, less sensitive to chemotherapy. This difference of treatment efficacy could be explained by the redox status of these tumours, High OXPHOS exhibiting a chronic oxidative stress and an accumulation of reactive oxygen species. Ferrocifens, bio-organometallic compounds, are believed to be ROS producers with a good cytotoxicity on ovarian cancer cell lines. The aim of this study was to evaluate the in vivo efficacy of ferrocifen stealth lipid nanocapsules on High and Low OXPHOS ovarian Patient-Derived Xenograft models, alone or in combination to standard chemotherapy. Accordingly, two ferrocifens, P53 and P722, were encapsulated in stealth LNCs. The treatment by stealth P722-LNCs in combination with standard chemotherapy induced, with a concentration eight time lower than in stealth P53-LNCs, similar tumour reduction on a Low OXPHOS model, allowing us to conclude that P722 could be a leading ferrocifen to treat ovarian cancer. This combination of treatments may represent a promising synergistic approach to treat resistant ovarian adenocarcinoma.
Fichier principal
Vignette du fichier
Idlas_2022_Ferrocifen stealth LNCs and conventional chemotherapy_a promising combination against multidrug-resistant ovarian adenocarcinoma.pdf (1.25 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03774820 , version 1 (12-09-2022)

Identifiants

Citer

Pierre Idlas, Abdallah Ladaycia, Fariba Némati, Elise Lepeltier, Pascal Pigeon, et al.. Ferrocifen stealth LNCs and conventional chemotherapy: A promising combination against multidrug-resistant ovarian adenocarcinoma. International Journal of Pharmaceutics, 2022, 626, pp.122164. ⟨10.1016/j.ijpharm.2022.122164⟩. ⟨hal-03774820⟩
78 Consultations
305 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More